United Therapeutics (NASDAQ:UTHR) Price Target Raised to $600.00

United Therapeutics (NASDAQ:UTHR) had its price objective boosted by Oppenheimer from $575.00 to $600.00 in a report released on Thursday, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Other analysts also recently issued research reports about the company. TD Cowen raised their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Wells Fargo & Company raised their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Argus raised their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday. Bank of America reduced their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Finally, UBS Group increased their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $374.02 on Thursday. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $377.92. The stock has a market capitalization of $16.70 billion, a PE ratio of 16.43, a P/E/G ratio of 1.35 and a beta of 0.56. The stock has a 50-day simple moving average of $355.40 and a 200 day simple moving average of $316.65.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter last year, the company earned $5.38 EPS. The company’s quarterly revenue was up 22.9% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics will post 24.85 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $833,350.26. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the sale, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 25,000 shares of United Therapeutics stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total value of $8,084,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $833,350.26. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,412 shares of company stock valued at $33,971,508 in the last three months. Corporate insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC increased its stake in shares of United Therapeutics by 176.2% in the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after buying an additional 9,133 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of United Therapeutics by 19.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock valued at $5,901,000 after buying an additional 4,100 shares during the period. Comerica Bank increased its stake in shares of United Therapeutics by 5.9% in the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after buying an additional 9,244 shares during the period. Tri Locum Partners LP acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at $15,959,000. Finally, QRG Capital Management Inc. boosted its position in shares of United Therapeutics by 12.4% in the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after purchasing an additional 1,692 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.